Investigating the poor outcomes ofBRAF-mutant advanced colorectal cancer: analysis from 2530 patients in randomised clinical trials
Jenny F. Seligmann(University of Leeds), Gary Middleton(University Hospitals Birmingham NHS Foundation Trust), Susan D. Richman(University of Leeds), Faye Elliott(University of Leeds), Philip Quirke(University of Leeds), Michel Seymour(University of Leeds), Sarah Brown(University of Leeds), David J. Fisher(MRC Clinical Trials Unit at UCL), Tim Maughan(University of Liverpool), Jeremy P. Cheadle(Cardiff University), Christopher G. Smith, Richard Adams(Velindre Cancer Centre)
Cited by 165
Related Papers
Leucovorin and Fluorouracil With or Without Oxaliplatin as First-Line Treatment in Advanced Colorectal Cancer
|Journal of Clinical Oncology|2000|3.8k
Association Between Administration of Systemic Corticosteroids and Mortality Among Critically Ill Patients With COVID-19
|JAMA|2020|2.4k
Capecitabine and Oxaliplatin for Advanced Esophagogastric Cancer
|New England Journal of Medicine|2008|2.3k
Preoperative radiotherapy versus selective postoperative chemoradiotherapy in patients with rectal cancer (MRC CR07 and NCIC-CTG C016): a multicentre, randomised trial
|The Lancet|2009|1.5k
Localised colon cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
|Annals of Oncology|2020|1.3k